Monthly Archives: August 2015

Biopharmaceutical News Week 34

Acquisitions /mergers/joint-ventures Valeant acquires Sprout (Canada) for $1 billion just two days after Sprout won US FDA approval for Addyi (flibanserin) as the world’s first female low libido treatment. According to the terms of the deal Valeant will acquire Sprout in an all-cash deal, around $500 million as an upfront payment, an additional $500 million […]

read more

Biopharmaceutical News Week 33

Acquisitions /mergers/joint-ventures Roche acquires GeneWEAVE Biosciences (USA), a privately held diagnostic company, and extends its footprint in the antibiotic field. Under the terms of the agreement, Roche will pay $190 million upfront and up to $235 million in contingent product related milestones. The acquisition provides Roche with GeneWEAVE’s Smarticles technology, an innovative class of molecular […]

read more

Biopharmaceutical News Week 32

  Acquisitions /mergers/joint-ventures   Shire acquires Foresight Biotherapeutics, an eye disease company in a deal worth $300 million. … and made an unsolicited offer of $30 billion to acquire, Baxalta, the newly spun off drug company out of Baxter Laboratories. According to Shire management the combined companies would generate $20 billion in sales by 2020, with […]

read more

Biopharmaceutical News Week 31

Acquisitions /mergers/joint-ventures   Teva acquires Allergan for $40.5 billion and forget everything you have been reading over the last months about the Teva-Mylan deal. Now the Israeli-based company has announced its intention to acquire Allergan’s generic business through a deal structured around $33.75 billion in cash and shares valued at $6.75 billion giving Allergan a […]

read more

Biopharmaceutical News Week 29/30

Acquisitions /mergers/joint-venture   Celgene acquires Receptos for $7.2 billion and gets access to ozanimod, a novel, potential best-in-class, oral, once-daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) as a treatment for ulcerative colitis and relapsing multiple sclerosis. Valeant Pharmaceuticals acquires Amoun Pharmaceutical (Egypt) in a deal worth $800 million and gives the company a […]

read more